The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals

Cardiovasc Res. 2001 Oct;52(1):153-60. doi: 10.1016/s0008-6363(01)00359-5.

Abstract

Objective: Previous studies have reported that the beta and alpha adrenoceptor blocker carvedilol has unique protective effects on free radical-induced myocardial injury. The aim of this study was to examine how carvedilol regulates reactive-oxygen-species-mediated signaling and decreases red blood cell membrane damage in heart perfusion and in a rheological model.

Methods: The ischemia-reperfusion-induced oxidative cell damage, and changes in the intracellular signaling mediated by reactive oxygen species and peroxynitrite were studied on rat hearts in a Langendorff perfusion system (n=15). The effect of carvedilol on red blood cell suspension viscosity (hematocrit: 60%) incubated with free radical generator (phenazine methosulphate) was also investigated (n=10). The measurements were performed on a capillary viscosimeter.

Results: In both studies a protective effect of carvedilol was found, as the decrease of red blood cell suspension viscosity and K(+) concentration in the supernatant indicated. Carvedilol significantly decreased the ischemia-reperfusion-induced free radical production and the NAD(+) catabolism and reversed the poly- and mono(ADP-ribosyl)ation. Carvedilol also decreased the lipid peroxidation and membrane damages as determined by free malondialdehyde production and the release of intracellular enzymes. The self ADP-ribosylation of isolated poly(ADP-ribose) polymerase was also significantly inhibited by carvedilol.

Conclusion: Our results show that carvedilol can modulate the reactive-oxygen-species-induced signaling through poly- and mono(ADP-ribosyl)ation reactions, the NAD(+) catabolism in postischemic perfused hearts and has a marked scavenger effect on free radical generator-induced red blood cell membrane damage. All these findings may play an important role in the beneficial effects of carvedilol treatment in different cardiovascular diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP Ribose Transferases
  • Adenosine Diphosphate Ribose / metabolism*
  • Adrenergic Antagonists / pharmacology*
  • Animals
  • Blood Viscosity / drug effects
  • Carbazoles / pharmacology*
  • Carvedilol
  • Erythrocyte Membrane / metabolism
  • Hemorheology
  • Humans
  • Lipid Peroxidation / drug effects
  • Male
  • Myocardial Reperfusion Injury / metabolism*
  • NAD / metabolism
  • Perfusion
  • Poly(ADP-ribose) Polymerases / metabolism
  • Propanolamines / pharmacology*
  • Rats
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism*
  • Signal Transduction / drug effects

Substances

  • Adrenergic Antagonists
  • Carbazoles
  • Propanolamines
  • Reactive Oxygen Species
  • Carvedilol
  • NAD
  • Adenosine Diphosphate Ribose
  • ADP Ribose Transferases
  • Poly(ADP-ribose) Polymerases